X0306 4 2022-01-27 0 0001620463 Athira Pharma, Inc. ATHA 0001604834 Litton Mark James C/O ATHIRA PHARMA, INC. 18706 NORTH CREEK PARKWAY, SUITE 104 BOTHELL WA 98011 1 1 0 0 Chief Executive Officer Common Stock 2021-11-18 5 A 0 E 885 12.51 A 115758 D Common Stock 6563 I By Irrevocable Trust of OSL Common Stock 6563 I By Irrevocable Trust of SWL Common Stock 6563 I By Irrevocable Trust of WGL Stock Option (Right to Buy) 9.91 2022-01-27 4 A 0 400000 0.00 A 2032-01-26 Common Stock 400000 400000 D The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the Athira Pharma, Inc. 2020 Employee Stock Purchase Plan ("ESPP"), for the ESPP Purchase Period (as defined in the ESPP) of May 18, 2021 through November 18, 2021. This transaction is also exempt under Rule 16b-3(c). The Purchase Period ended November 18, 2021 and is the Purchase Period comprising the Offering Period (as defined in the ESPP) that began May 18, 2021. In accordance with the ESPP, these shares were purchased based on 85% of the closing price on November 18, 2021. Reflects Common Stock held by Irrevocable Trust of OSL held for the benefit of Dr. Litton's children. Reflects Common Stock held by Irrevocable Trust of SWL held for the benefit of Dr. Litton's children. Reflects Common Stock held by Irrevocable Trust of WGL held for the benefit of Dr. Litton's children. One-forty eighth (1/48th) of the shares subject to the option will vest on February 18, 2022, and one forty-eighth of the shares subject to the option will vest each month thereafter. /s/ Glenna Mileson, Attorney-in-fact on behalf of Mark Litton 2022-01-31